Question explored with the scientific record
Do fecal transplants work for ibs
The short version: the evidence for FMT in IBS is promising but thin, and the best study so far is a pilot with no placebo group.
The most useful study is a 2025 Korean pilot that gave 44 moderate-to-severe IBS patients a single-donor FMT [2]. At 12 weeks, the average IBS symptom severity score dropped from about 340 to 273, a statistically significant change. About 20 of 37 patients who completed the study were classified as responders. The microbiome shifted toward the donor’s profile, and those shifts correlated with symptom improvement. That sounds encouraging, but there is no placebo arm. Without one, you cannot separate the real effect from the natural course of IBS or the powerful placebo response that gut-directed treatments routinely produce.
The rest of the evidence is weaker. A 2020 case series of 17 adults with chronic diarrhea included 6 IBS patients and reported symptom improvement, but it was an open-label series with no control group [1]. A 2021 review confirmed that the gut-brain axis is real in IBS and that microbiota-targeted therapies have a plausible mechanism, but it did not test FMT directly [3]. A 2025 protocol describes a planned randomized placebo-controlled trial of FMT for IBS, but it has not reported results yet [10]. That is the study design the field actually needs.
The safety record from the C. difficile literature is relevant but not directly transferable. In recurrent C. diff, FMT works well: a systematic review of encapsulated FMT found response rates around 80-90% after one or two treatments [4], and frozen FMT appears as effective as fresh [5]. But C. diff is a single-pathogen disease where recolonizing the gut with a healthy donor’s flora directly competes with the pathogen. IBS is a complex, heterogeneous disorder with no single microbial target. The same intervention may not work the same way.
Serious harms are rare but documented. A case report described a Crohn’s patient who developed E. coli bacteremia after FMT [9]. A 2018 observational study of FMT for C. diff found a 16.7% failure rate, with most failures occurring within the first month [7]. Donor screening is rigorous but not perfect: one study found that only 9 of 21 potential donors passed screening [8]. A 2025 commentary raised the concept of “microbiome mismatching,” where donor microbiota from one gut region may not engraft properly in another, potentially causing off-target metabolic or immune effects [6]. These are real unknowns.
My call: FMT for IBS is an experimental treatment with a plausible mechanism and some positive pilot data, but no placebo-controlled trial has confirmed its benefit. The evidence is not strong enough to recommend it outside a research setting. Confidence: low.
Sources used 10
-
Diarrhoea And Intestinal Microbiota
A small case-series of 17 adults with chronic diarrhoea and diverse comorbidities suggests intestinal microbiota transplantation (IMT) can reduce diarrhoeal symptoms and improve several co-occurring conditions, with mostly mild complications and considerations for donor screenin…
DOI: 10.31579/2690-8808/006 -
Predictors of Treatment Response to Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Pilot Study
A Korean single-donor FMT pilot study in moderate-to-severe IBS patients evaluating safety, efficacy, and predictors of response, showing symptom relief and durable gut microbiota shifts associated with donor engraftment and baseline microbial features.
DOI: 10.5056/jnm24183 -
The gut–brain axis in irritable bowel syndrome and inflammatory bowel disease
This review synthesizes evidence on the gut-brain axis in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), highlighting bidirectional gut–brain interactions, mood disorder comorbidity, microbiota alterations, and the therapeutic potential of psychobiotics.
DOI: 10.1016/j.dld.2020.11.026 -
Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review
This systematic review evaluates the safety and efficacy of encapsulated fecal microbiota transplantation (FMT) for recurrent Clostridium difficile infection, finding it to be safe and effective with a high response rate and few adverse events.
DOI: 10.1097/meg.0000000000001147 -
Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?
This meta-analysis investigates the efficacy of frozen fecal microbiota transplantation (FMT) compared to fresh FMT in patients with recurrent or refractory Clostridium difficile infection, concluding that both methods are equally effective.
DOI: 10.1016/j.diagmicrobio.2017.05.007 -
Microbiota transplants: the concept of ‘microbiome mismatching’ explored
This is a commentary on DeLeon et al.'s Cell 2025 study showing that the source of donor microbiota (jejunal, caecal, or faecal) differentially engrafts across the host gut, alters metabolomic and hepatic transcriptomic profiles, and raises cautions about microbiome mismatching …
DOI: 10.1038/s41392-025-02464-9 -
Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures
This observational study investigates the timing and characteristics of fecal microbiota transplantation (FMT) failures in patients with recurrent Clostridium difficile infection, revealing that most failures occur within the first four weeks post-transplant.
DOI: 10.1016/j.cgh.2017.10.031 -
Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection
This study evaluates the experience of donor recruitment, screening, retention, and perceptions of stool donors for fecal microbiota transplantation (FMT) in patients with recurrent Clostridium difficile infection.
DOI: 10.1097/MCG.0000000000000768 -
Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection
This case report discusses a 61-year-old male with Crohn's disease who developed bacteremia after fecal microbiota transplantation for recurrent Clostridium difficile infection, highlighting the potential complications associated with FMT in patients with IBD.
DOI: 10.1016/j.crohns.2013.10.002 -
The Effect of Faecal Microbiota Transplantation on Cognitive Function in Cognitively Healthy Adults with Irritable Bowel Syndrome: Protocol for a Randomised, Placebo-Controlled, Double-Blinded Pilot Study
This protocol describes a randomized, double-blind, placebo-controlled pilot study to assess the feasibility and potential cognitive effects of a single fecal microbiota transplantation dose in cognitively healthy adults with irritable bowel syndrome, with longitudinal cognitive…
DOI: 10.3390/mps8040083